550 related articles for article (PubMed ID: 24656451)
1. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
[TBL] [Abstract][Full Text] [Related]
2. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
[TBL] [Abstract][Full Text] [Related]
4. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
7. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
10. Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
Toyoda H; Wada H; Miyata T; Amano K; Kihira K; Iwamoto S; Hirayama M; Komada Y
J Pediatr Hematol Oncol; 2016 Apr; 38(3):e137-9. PubMed ID: 26840081
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
14. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
15. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome.
Wetzels JF; van de Kar NC
Am J Kidney Dis; 2015 Feb; 65(2):342. PubMed ID: 25616634
[No Abstract] [Full Text] [Related]
17. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.
Ardissino G; Tel F; Sgarbanti M; Cresseri D; Giussani A; Griffini S; Grovetto E; Possenti I; Perrone M; Testa S; Paglialonga F; Messa P; Cugno M
Pediatr Nephrol; 2018 Mar; 33(3):457-461. PubMed ID: 29046944
[TBL] [Abstract][Full Text] [Related]
18. In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'.
Ardissino G; Possenti I; Tel F
Am J Kidney Dis; 2015 Feb; 65(2):342-3. PubMed ID: 25616633
[No Abstract] [Full Text] [Related]
19. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
20. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
